CorMedix (CRMD) Cash from Financing Activities (2012 - 2025)

CorMedix has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$1.4 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at -$1.4 million, down 112.52% year-over-year; the trailing twelve-month figure through Dec 2025 was $238.5 million (up 806.01% YoY), and the FY2025 annual result was $238.5 million, up 806.01% from the prior year.
• Cash from Financing Activities came in at -$1.4 million for Q4 2025 at CorMedix, down from $150.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $150.5 million in Q3 2025 to a low of -$1.4 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $6.1 million (2022), against an average of $21.1 million.
• Across the five-year window, Cash from Financing Activities soared 9710.09% in 2023 and slumped 112.52% in 2025, its largest moves.
• CorMedix's Cash from Financing Activities stood at $176992.0 in 2021, then surged by 3315.74% to $6.0 million in 2022, then tumbled by 92.26% to $467650.0 in 2023, then soared by 2313.18% to $11.3 million in 2024, then sank by 112.52% to -$1.4 million in 2025.
• The last three Cash from Financing Activities figures came in at -$1.4 million (Q4 2025), $150.5 million (Q3 2025), and $83.2 million (Q2 2025), per Business Quant data.